Novartis | NOVN - Betriebsaufwand

Aktienkurs
119.14
Täglich Wechseln
-0.38 -0.32%
Monatlich
-8.33%
Jährlich
20.81%
Q1 Prognose
116.14




Betriebsaufwand Veränderung Datum
AbbVie USD 10.81B 13.45B 2025-12
Alcon AG USD 2.41B 123M 2025-12
Almirall EUR 517.4M 32K 2025-12
Amgen USD 5.9B 773M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Autolus Therapeutics Ltd USD 96.76M 3.94M 2025-12
Bayer EUR 10.33B 126M 2025-12
Biogen USD 1.88B 81.4M 2025-09
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Fresenius EUR 5.25B 337M 2025-12
Fresenius Medical Care EUR 4.41B 27.91M 2025-12
Galapagos EUR 120.26M 7.43M 2025-12
Genmab DKK 798M 235M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
GRIFOLS EUR 1.71B 193M 2025-12
Hikma Pharmaceutical USD 1.34B 702M 2025-12
J&J USD 18.97B 2.38B 2025-12
Lonza CHF 2.9B 184M 2025-06
Merck EUR 4.78B 669M 2025-12
Merck USD 10.16B 558M 2025-12
Novartis USD 9.8B 61M 2025-12
Novartis USD 9.8B 23M 2025-12
Novo Nordisk DKK 46.76B 3.99B 2025-12
Orion EUR 367.1M 64.9M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Philips EUR 4.38B 405M 2025-12
Recordati EUR 384.01M 82.67M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 10.51B 1.21B 2025-12
UCB EUR 2.96B 196M 2025-12